Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
Peking University People's Hospital
30 participants
Apr 25, 2024
INTERVENTIONAL
Conditions
Summary
To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and providing a basis for clinical application.
Eligibility
Inclusion Criteria5
- Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition)
- Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy
- BSA≥5%
- Sign the informed consent and be willing to undergo surgical treatment
- -65 years old, both genders
Exclusion Criteria4
- Severe visceral or infectious disease not suitable for surgical treatment
- Tendency toward keloid formation
- Coagulation defects
- Unable to complete follow-up on time
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1. Thin split thickness skin grafts were taken from the donor site (anterolateral thigh) after application of topical anaesthesia under complete aseptic precautions. 2. The cell suspension was prepared by the cell sorting kit (Primcell, Jiangsu Repatec Life Science Co.,Ltd). 3. Then the recipient skin was uniformly dermabraded using an electrical dermabrader set at 10,000 to 20,000 rpm until punctate bleeding points appeared. 4. The cell suspension was applied onto the dermabraded recipient area. 5. The recipient site was then fixed firmly with dressings and elastic bandage. The dressings were removed 10 days after transplantation.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07187882